ADJUVANCE TECHNOLOGIES INC. — Department of Health and Human Services SBIR Phase I: NIAID

Description

Increasingly defined vaccines against infectious diseases are better tolerated but less immunogenicrequiring use of an immunological adjuvant for best effectAdjuvance s semi synthetic saponin adjuvant TiterQuilTQLhas shown remarkable efficacy with a variety of antigens with no detectable reactogenicityWhen combined withof the leading vaccines against influenzaFluzoneFluarix and Flublokstriking augmentation of the antibody response against the A H NhemagglutininHAantigen and more thanfold vaccine dose saving was seen with allvaccines but this was most striking with the most defined and least immunogenic vaccineFlublokThe objectives of this Phaseproposal areto determine if this augmentation applies to the otherantigens in Flu vaccinesA H Nand Bto determine if it applies to the T cell responsesto conduct an IND enabling stability study of Flublokandto determine whether mixture of TQLand Flublok with additional immunological adjuvants further augments the serologic or especially T cell response to the HA antigenSuccessful completion of this study will support initiation of IND enabling studies in a PhaseSBIR application for Flublok plus TQLand use of TiterQuilwith other types of vaccines